Oleg Yevtushenko, the Executive Director of Rostec Corporation, announced the plans to expand the national calendar of vaccinations by using new vaccines. Their manufacturing will be set up at the facilities of Nacimbio and commercial sites.
“We have this idea of launching five new vaccines in five years. In particular, we are trying to enter the market of vaccines against papilloma virus infection, rotavirus vaccine, pneumococcal vaccine, as well as varicella vaccine and others,” said Oleg Yevtushenko.
Nacimbio works on expanding the manufacturing of Russian-made medicinal products. In particular, the company signed an agreement with Pharmstandard and Kedrion Biopharma, an Italian company, on establishing Kirov Plasma, a joint-stock company. The enterprise will be implementing a program on manufacturing the medicines derived from human blood plasma at the facilities of the plant in the Russian city of Kirov. Nacimbio will complete the construction and technical equipment of the plant, validate the manufacturing of blood products, with the subsequent manufacturing and sales of products within the Eurasian Economic Union.
In addition, this year, Nacimbio concluded a number of agreements with foreign and Russian companies on manufacturing the medicinal products. In particular, Nacimbio together with Ishvan Pharmaceutical Ltd (UAE) established a company Pharm Aid. The enterprise will be engaged in the transfer of technology for manufacturing new combination medicinal products and active pharmaceutical substances for the treatment of hepatitis C, HIV, and tuberculosis.